Increasing global thyroid disease burden, geriatric population growth, and automation in diagnostic laboratories fuel steady 5.58% CAGR growth in thyroid…
The firsta approved fully-human, dual-acting interleukin-23 (IL-23) inhibitor in moderately to severely active ulcerative colitis,1,2,3,4,5 guselkumab showed statistically higher rates…